SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual Meeting

SEATTLE — May 29, 2019 — The 55th Annual meeting will offer educational and scientific sessions in all disciplines of oncology, for more than 40,000 oncologists from across the world to attend. SCCA’s physician researchers will offer a range of information related to immunotherapy treatment options for solid tumors including checkpoint inhibitors and combination immunotherapy. Abstracts and seminars related to genetics and breast cancer adjuvant therapy also are planned. Following is a list in chronological order of abstracts and research that will be delivered by SCCA physicians:

Friday May 31, 7:30 a.m

• Case #3: Prostate Cancer: The Genetic Landscape and Prognostic/Predictive Implications by Heather H. Cheng, MD, PhD. Dr. Cheng leads SCCA’s Prostate Cancer Genetics Clinic and cares for patients with prostate, bladder and testicular cancers.

Saturday, June 1, from 1:15 p.m.

• Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study by Evan Ya-Wen Yu, MD. Dr Yu is a medical oncologist who treats prostate, bladder and testicular cancer.

• Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC) by Laura Graham, MD. Dr. Graham is a fellow who specializes in hematology oncology.

Saturday, June 1, 4:30 p.m.

• Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results by John B. Liao, MD, PhD. Dr. Liao specializes in caring for women with cervical cancer, endometrial cancer, ovarian cancer, and other gynecologic cancers.

Sunday, June 2, 8:20 a.m.

• Molecular Imaging Techniques in Breast Cancer by Hannah M. Linden, MD. Dr. Linden specializes in endocrine treatment of breast cancer.
  Sun, June 2, 9:36 AM

• On the Path to Effective, Patient-Centered Policy by Veena Shankaran, MD. Dr. Shankaran is a medical oncologist who specializes in caring for patients with gastrointestinal malignancies, with a particular focus on cancers of the esophagus and stomach.

Sunday, June 2, 11:21 a.m.

• Advances in Advanced Disease by William P. Harris, MD. Dr. Harris specializes in caring for people with gastrointestinal malignancies including hepatobiliary and pancreatic cancer.

Sunday, June 2, 4:15 p.m.

• Post-Plenary Clinical Application and Discussion: Prostate Cancer (LBA2) by Celestia S. Higano, MD. Dr. Higano is a medical oncologist who specializes in treating prostate cancer

Sunday, June 2, 4:45 p.m.

• Developmental Immunotherapy and Tumor Immunobiology; Developmental Therapeutics and Tumor Biology (Nonimmuno); Genitourinary (Nonprostate) Cancer; Immunotherapy by Petros Grivas, MD, PhD. Dr. Grivas is a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate cancer and testis cancer.

Monday, June 3, 7:30 a.m.

• Developmental Immunotherapy and Tumor Immunobiology by Mary (Nora) L. Disis, MD. Dr. Disis is a medical oncologist researching vaccines and immunotherapy for cancer, specifically breast cancer vaccines, including the role of the human immune system in battling cancer.

Monday, June 3, 8:00 a.m.

• ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high risk diffuse large B cell lymphoma patients with novel genomic biomarker DGM1 by Stephen D. Smith, MD. Dr. Smith is a medical oncologist who treats patients with lymphoma and other blood disorders.

• Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)? by Eric Chow, MD, MPH. Dr. Chow is the medical director of Seattle Children's Pediatric Cancer Long Term Follow-up Program.

Monday, June 3, 11:30 a.m.

• A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic/unresectable sarcoma by Seth M. Pollack, MD. Dr. Pollack is a medical oncologist who treats adult patients with sarcoma.

Monday, June 3, 1:15 p.m.

• Interdisciplinary management of Germ Cell Tumors: Surgical Oncology Perspective by Daniel W. Lin, MD. Dr. Daniel W. Lin is the Chief of Urologic Oncology at the University of Washington's Department of Urology and a urologist specializing in genitourinary oncologic surgery.

• Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents by Ali Raza Khaki, MD. Dr. Khaki is a fellow who specializes in hematology oncology. 

• A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14) by Evan Ya-Wen Yu, MD. Dr Yu is a medical oncologist who treats prostate, bladder and testicular cancer.

• PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer by Petros Grivas, MD, PhD. Dr. Grivas is a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate cancer and testis cancer.

• First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A by Scott S. Tykodi, MD, PhD. Dr. Tykodi is a medical oncologist who treats kidney cancer and melanoma. He is particularly interested in the application of immune therapies to the treatment of cancer.

Wednesday, June 5, 8:00 a.m.

• ‘Breast Cancer - Local/Regional/Adjuvant’ by Nancy E. Davidson, MD. Dr. Davidson is the executive director of SCCA and treats patients with breast cancer.

As Washington state’s only NCI-designated cancer center, SCCA is committed to delivering patient-centered, state-of-the-art care through a multidisciplinary approach that combines cancer experts, comprehensive care from referrals to survivorship, and groundbreaking treatment. SCCA has been ranked among the top 10 cancer centers in the United States for 13 consecutive years by U.S. News and World Report for hospital rankings.

A pioneer in accelerating progress against cancer, SCCA affords patients access to over 500 clinical trials each year, building on the legacy of E. Donnall Thomas, MD who pioneered bone marrow transplants. Dr. Thomas received the 1990 Nobel Prize for his discovery. This led to establishment of the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance. Doctors at the Fred Hutch Bone Marrow Transplant Program at SCCA have performed more than 16,000 bone marrow transplants, more than any other institution in the world.

“Providing the best care possible to patients is at the heart of our mission,”said F. Marc Stewart, MD, medical director and senior vice president at Seattle Cancer Care Alliance. “We’re truly humbled by the work of our physician researchers who work everyday to support bench to bedside ground-breaking treatments and care for every patient.”

ASCO 2019 offers education and scientific sessions in all disciplines of oncology for 40,000 oncologists from across the world to attend. To view abstracts and data following each session, visit ASCO.

Media Contact:
Fred Hutch Media Team
media@fredhutch.org